UCB, Brussels, is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 700 people in 36 countries, the company generated revenue of € 5.5 billion in 2022.

Authors

Dhaval Patel

Dhaval Patel, Executive Vice President & Chief Scientific Officer Dhaval Patel has over 30 years of experience in R&D and immunology, more specifically with Novart...

❮ ❯

Interviews

26297

AI Based Drug Discovery & Development – ...